Variant Summary
- Also known as
- EML4-ALK
- HGVS
- —
- Variant Type(s)
- transcript_fusion
- Evidence Items
- 8
Evidence Level Distribution
Level C: 4Level D: 4
Evidence Items
Showing CIViC evidence rows where gene = EML4::ALK and variant = Fusion.
| Level | Type | Direction | Significance | Disease | Drugs | Rating |
|---|---|---|---|---|---|---|
| D | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | WHI-P154 | 5 |
| D | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Retaspimycin Hydrochloride,Crizotinib | 4 |
| C | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Crizotinib | 4 |
| C | Predictive | Supports | Sensitivity/Response | Lung Adenocarcinoma | Crizotinib | 4 |
| C | Predictive | Supports | Sensitivity/Response | Malignant Pleural Mesothelioma | Alectinib | 4 |
| C | Predictive | Supports | Resistance | Lung Acinar Adenocarcinoma | Erlotinib | 2 |
| D | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Alvespimycin,Crizotinib | 2 |
| D | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Lorlatinib | 2 |